{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:02:23Z","timestamp":1789984943114,"version":"4.0.1"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer's disease (AD) is a neurodegenerative condition marked by the accumulation of beta\u2010amyloid plaques and neurofibrillary tangles, leading to neuronal death and cognitive decline. Acetylcholinesterase inhibitors (AChEIs) such as donepezil, galantamine, and rivastigmine are commonly used to enhance cognitive function by increasing acetylcholine levels, but they can cause side effects like nausea, bradycardia, and headaches. NMDA receptor antagonists, like memantine, reduce glutamatergic activity and are used to manage symptoms, yet are also associated with adverse effects including dizziness and agitation. Recently, monoclonal antibodies such as aducanumab have been developed to target amyloid\u2010beta aggregates, though they are associated with amyloid\u2010related imaging abnormalities (ARIA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This article aims to summarize current pharmacological approaches to AD and to highlight the emerging role of Donanemab\u2010azbt, an FDA\u2010approved monoclonal antibody for early symptomatic AD, in reducing amyloid plaques and slowing cognitive decline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This overview synthesizes data from clinical trials and therapeutic experience with acetylcholinesterase inhibitors, NMDA receptor antagonists, and monoclonal antibodies, with a particular focus on Donanemab\u2010azbt, its mechanism of targeting amyloid\u2010beta aggregates, and its efficacy and safety profile in early symptomatic AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Donanemab\u2010azbt has demonstrated efficacy in clinical trials, significantly reducing amyloid plaque burden and slowing cognitive decline in patients with early symptomatic AD. However, its use may result in ARIA and other adverse effects, necessitating careful clinical and radiological monitoring during treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the risks of ARIA and other adverse events, Donanemab\u2010azbt represents a promising addition to AD therapy, offering the potential for improved outcomes in patients with early symptomatic disease and expanding the therapeutic options beyond traditional symptomatic treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hsr2.72688","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:57:02Z","timestamp":1782133022000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FDA Approval of Donanemab\u2010azbt: A New Dawn in Alzheimer's Disease Treatment"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2277-0183","authenticated-orcid":false,"given":"Rumaisa","family":"Riaz","sequence":"first","affiliation":[{"name":"Internal Medicine Dow University of Health Sciences (DUHS) Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marrium","family":"Fatima","sequence":"additional","affiliation":[{"name":"Internal Medicine Dow University of Health Sciences (DUHS) Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Ramzan","sequence":"additional","affiliation":[{"name":"Internal Medicine Dow University of Health Sciences (DUHS) Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diya","family":"Rathi","sequence":"additional","affiliation":[{"name":"Internal Medicine Dow University of Health Sciences (DUHS) Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filzah","family":"Fatima","sequence":"additional","affiliation":[{"name":"Internal Medicine Dow University of Health Sciences (DUHS) Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Farooq","sequence":"additional","affiliation":[{"name":"Internal Medicine Dow University of Health Sciences (DUHS) Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1541-3037","authenticated-orcid":false,"given":"Ayesha","family":"Shaukat","sequence":"additional","affiliation":[{"name":"Internal Medicine Dow University of Health Sciences (DUHS) Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawal","family":"Khaliq","sequence":"additional","affiliation":[{"name":"Internal Medicine Dow University of Health Sciences (DUHS) Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-1215","authenticated-orcid":false,"given":"Aymar","family":"Akilimali","sequence":"additional","affiliation":[{"name":"Department of Research, Medical Research Circle (MedReC) Goma Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2022.06.021"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01484-7"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-024-04333-y"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25136928"},{"key":"e_1_2_9_6_1","first-page":"1","article-title":"Alzheimer Disease (Nursing)","volume":"1","author":"Kumar A.","year":"2024","journal-title":"StatPearls [Internet]"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-200483"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124306"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199915050-00004"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65887-4"},{"key":"e_1_2_9_11_1","first-page":"1","article-title":"Alzheimer Disease","volume":"1","author":"Kumar A.","year":"2024","journal-title":"StatPearls"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400020021006"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-200304000-00011"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200118110-00006"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.4235\/agmr.21.0079"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1590\/1516-3180.2015.01980112"},{"issue":"3","key":"e_1_2_9_17_1","first-page":"247","article-title":"Drug Treatments in Alzheimer's Disease","volume":"16","author":"Briggs R.","year":"2016","journal-title":"Clinical Medicine, Journal of the Royal College of Physicians of London"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831070-00003"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S325026"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.25259\/JNRP_356_2023"},{"key":"e_1_2_9_21_1","first-page":"1","article-title":"Major Neurocognitive Disorder (Dementia)","volume":"1","author":"Emmady P. D.","year":"2022","journal-title":"StatPearls"},{"key":"e_1_2_9_22_1","unstructured":"FDA Approves Treatment for Adults With Alzheimer's Disease | FDA [Internet]. [cited 2025 May 31]. Available from:https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease."},{"key":"e_1_2_9_23_1","unstructured":"fda cder. HIGHLIGHTS OF PRESCRIBING INFORMATION Monoclonal Antibodies Directed Against Aggregated Forms of Beta Amyloid Including KISUNLA Can Cause Amyloid Related Imaging Abnormalities (ARIA) as ARIA With Edema (ARIA\u2010E) and ARIA With Hemosiderin Deposition (ARIA\u2010H). [cited 2025 May 31]; Available from:www.fda.gov\/medwatch."},{"key":"e_1_2_9_24_1","unstructured":"FDA Approves Treatment for Adults With Alzheimer's disease | FDA [Internet]. [cited 2025 May 31]. Available from:https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease."},{"key":"e_1_2_9_25_1","unstructured":"Study Results | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER\u2010ALZ 2) | ClinicalTrials.gov [Internet]. [cited 2025 May 31]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT04437511?tab=results."},{"key":"e_1_2_9_26_1","unstructured":"FDA Approves Eli Lilly's Kisunla For Early\u2010Stage Alzheimer's Patients \u2010 Health Policy Watch [Internet]. [cited 2025 May 31]. Available from:https:\/\/healthpolicy-watch.news\/fda-approves-eli-lillys-kisunla-for-early-stage-alzheimers-patients\/."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1148\/rg.230009"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.72688","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hsr2.72688","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.72688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:17:39Z","timestamp":1789982259000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.72688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/hsr2.72688"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.72688","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-05-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72688"}}